Search Results - "Rosen, Oliver"

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group by Lin, Nancy U, Prowell, Tatiana, Tan, Antoinette R, Kozak, Marina, Rosen, Oliver, Amiri-Kordestani, Laleh, White, Julia, Sul, Joohee, Perkins, Louise, Beal, Katherine, Gaynor, Richard, Kim, Edward S

“…Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority…”
Get full text

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants by Smith, Bryan D., Kaufman, Michael D., Lu, Wei-Ping, Gupta, Anu, Leary, Cynthia B., Wise, Scott C., Rutkoski, Thomas J., Ahn, Yu Mi, Al-Ani, Gada, Bulfer, Stacie L., Caldwell, Timothy M., Chun, Lawrence, Ensinger, Carol L., Hood, Molly M., McKinley, Arin, Patt, William C., Ruiz-Soto, Rodrigo, Su, Ying, Telikepalli, Hanumaiah, Town, Ajia, Turner, Benjamin A., Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen, Janku, Filip, Abdul Razak, Albiruni Ryan, Rosen, Oliver, Heinrich, Michael C., Flynn, Daniel L.

“…Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms,…”
Get full text

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials by KABBINAVAR, Fairooz F, HURWITZ, Herbert I, JING YI, SARKAR, Somnath, ROSEN, Oliver

“…Colorectal cancer (CRC) occurs predominantly in older persons. To provide more statistical power to assess risk/benefit in older patients, we examined the…”
Get full text

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy by BAGRI, Anil, BERRY, Leanne, ROSEN, Oliver, PLOWMAN, Greg D, GUNTER, Bert, SINGH, Mallika, KASMAN, Ian, DAMICO, Lisa A, HONG XIANG, SCHMIDT, Maike, FUH, Germaine, HOLLISTER, Beth

“…Inhibition of the vascular endothelial growth factor (VEGF) axis is the basis of all currently approved antiangiogenic therapies. In preclinical models,…”
Get full text

First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments by Naing, Aung, Khalil, Danny, Rosen, Oliver, Camidge, D Ross, Lillie, Tom, Ji, Rui-Ru, Stacey, Andrea, Thomas, Matthew, Rosen, Lee

“…BackgroundTumor-selective oncolytic viral vectors are promising anticancer therapeutics; however, challenges with dosing and potency in advanced/metastatic…”
Get full text

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia by Cortes, Jorge, Talpaz, Moshe, Smith, Hedy P, Snyder, David S, Khoury, Jean, Bhalla, Kapil N, Pinilla-Ibarz, Javier, Larson, Richard, Mitchell, David, Wise, Scott C, Rutkoski, Thomas J, Smith, Bryan D, Flynn, Daniel L, Kantarjian, Hagop M, Rosen, Oliver, Van Etten, Richard A

“…A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5'-triphosphate-binding pocket and are affected by evolving mutations…”
Get full text

Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618 by George, Suzanne, Heinrich, Michael C., Abdul Razak, Albiruni Ryan, Chi, Ping, Gordon, Michael S., Ganjoo, Kristen N., von Mehren, Margaret, Somaiah, Neeta, Trent, Jonathan C., Su, Ying, Ruiz-Soto, Rodrigo, Rosen, Oliver, Janku, Filip

“…Abstract only…”
Get full text

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor by VANHOEFER, Udo, TEWES, Mitra, SEEBER, Siegfried, HARSTRICK, Andreas, BASELGA, José, ROJO, Federico, DIRSCH, Olaf, SCHLEUCHER, Norbert, ROSEN, Oliver, TILLNER, Joachim, KOVAR, Andreas, BRAUN, Ada H, TRARBACH, Tanja

“…To investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile of the humanized antiepidermal growth factor receptor…”
Get full text

765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial by O’Reilly, Eileen M, O’Hara, Mark H, Fisher, George, Wolff, Robert A, Wainberg, Zev A, Ko, Andrew H, Arnott, Jamie, Cabanski, Christopher R, Upadhaya, Samik, Saez-Ibanez, Ana Rosa, Campbell, Jay, Francis, James, Rosen, Oliver, Bucktrout, Samantha, Boffo, Silvia, Dugan, Ute, O’Donnell-Tormey, Jill, Vonderheide, Robert H, Khalil, Danny

“…BackgroundHistorically, the treatment of metastatic pancreatic adenocarcinoma (mPDAC) has had limited success. This is particularly true of conventional…”
Get full text

418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A02+ Patients with HPV16+ recurrent, or metastatic solid tumors by Eng, Cathy, Baranda, Joaquina, Taylor, Matthew, Gordon, Michael, Matulonis, Ursula, Janku, Filip, Kornacker, Martin, Kamat, Asha, Rosen, Oliver, Jimeno, Antonio

“…BackgroundSQZ-PBMC-HPV is a therapeutic cancer vaccine created with Cell Squeeze®, a proprietary cell-engineering system. SQZ-PBMC-HPV is a novel cancer…”
Get full text

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib by Janku, Filip, Abdul Razak, Albiruni R, Chi, Ping, Heinrich, Michael C, von Mehren, Margaret, Jones, Robin L, Ganjoo, Kristen, Trent, Jonathan, Gelderblom, Hans, Somaiah, Neeta, Hu, Simin, Rosen, Oliver, Su, Ying, Ruiz-Soto, Rodrigo, Gordon, Michael, George, Suzanne

“…In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic…”
Get full text

3061: Gut microbiome and gene expression changes during a Phase 1 trial of enadenotucirev and radiotherapy by Hillson, Lily V., Johnson, Jethro, Ji, Rui Ru, Rosen, Oliver, Qiao, Yu, Ooms, Alex, Maughan, Timothy S., Roxburgh, Campbell S., Hawkins, Maria, O'Cathail, Sean M.

Get full text

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K‐ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer by Hurwitz, Herbert I., Yi, Jing, Ince, William, Novotny, William F., Rosen, Oliver

“…Purpose. Mutations of the K‐ras gene were identified as a prognostic marker in metastatic colorectal cancer (mCRC). In addition, emerging data suggest that…”
Get full text

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system by Alexander, Tobias, Thiel, Andreas, Rosen, Oliver, Massenkeil, Gero, Sattler, Arne, Kohler, Siegfried, Mei, Henrik, Radtke, Hartmut, Gromnica-Ihle, Erika, Burmester, Gerd-Rüdiger, Arnold, Renate, Radbruch, Andreas, Hiepe, Falk

“…Clinical trials have indicated that immunoablation followed by autologous hematopoietic stem cell transplantation (ASCT) has the potential to induce clinical…”
Get full text

Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies by Hurwitz, Herbert I., Douglas, Pamela S., Middleton, John P., Sledge, George W., Johnson, David H., Reardon, David A., Chen, Dafeng, Rosen, Oliver

“…Background. Hypertension is associated with antivascular endothelial growth factor treatment, but the clinical implications of hypertension are uncertain. To…”
Get full text

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101 by Jimeno, Antonio, Baranda, Joaquina Celebre, Mita, Monica M., Gordon, Michael S., Taylor, Matthew H., Iams, Wade Thomas, Janku, Filip, Matulonis, Ursula A., Bernstein, Howard, Loughhead, Scott, Kornacker, Martin, Zwirtes, Ricardo F., Rosen, Oliver, Eng, Cathy

“…Abstract only 2536 Background: Ineffective MHC-I presentation of tumor antigens to CD8+ T cells limits T cell activation and the efficacy of cancer vaccines…”
Get full text

Abstract CT029: Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST) by Janku, Filip, Heinrich, Michael, Razak, Albiruni, Gordon, Michael, Chi, Ping, Ganjoo, Kristen, Mehren, Margaret von, Somaiah, Neeta, Lee, Jongtae, Kuida, Keisuke, Soto, Rodrigo Ruiz, Rosen, Oliver, George, Suzanne

“…Abstract Background: DCC-2618, a pan-KIT and PDGFRα kinase switch control inhibitor, is being studied in a pivotal, randomized phase 3 trial, INVICTUS…”
Get full text

Abstract LB-039: Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor by Janku, Filip, Razak, Albi, Gordon, Michael, Brooks, David, Flynn, Daniel, Gupta, Anu, Kaufman, Michael, Leary, Cynthia, Smith, Bryan, Westwood, Deb, Somaiah, Neeta, Helman, Elena, Gerstenberger, Eric, Rosen, Oliver, George, Suzanne

“…Abstract Background: DCC-2618 is a potent switch control inhibitor of KIT and PDGFRα kinases maintains potent inhibition of mutant forms across all exon…”
Get full text

ACTR-02. DCC-2618, A NOVEL pan-KIT AND PDGFRa KINASE SWITCH CONTROL INHIBITOR, SHOWS ENCOURAGING SIGNAL IN A PATIENT (PT) WITH GLIOBLASTOMA (GBM) by de Groot, John, George, Suzanne, Razak, Albiruni, Gordon, Michael, Janku, Filip, Ligon, Keith, Wen, Patrick, Friedlander, Sharon, Flynn, Daniel, Kaufman, Michael, Pitman, Jama, Ruiz-Soto, Rodrigo, Smith, Bryan, Westwood, Deborah, Rosen, Oliver, Reardon, David

Get full text

Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors by Janku, Filip, Abdul Razak, Albiruni Ryan, Gordon, Michael S., Brooks, David Glenn, Flynn, Daniel Lee, Kaufman, Michael, Pitman, Jama, Smith, Bryan Douglas, Somaiah, Neeta, De Groot, John Frederick, Chen, Guo, Jennings, Julia, Salah, Samer, Westwood, Deb, Gerstenberger, Eric, Rosen, Oliver, George, Suzanne

“…Abstract only 2515 Background: DCC-2618 is a potent switch control inhibitor of KIT and PDGFR kinases active in a broad range of mutations. GIST is an…”
Get full text